Deferasirox is an iron chelator and the first oral medication FDA approved for chronic iron overload in patients receiving long term blood transfusions.
Synonyms
Deferasiroxum
Deferasirox
Brand Names
Apo-deferasirox (type J)
Deferasirox Oral Granules
PMS-deferasirox (type J)
Deferasirox (type J)
Taro-deferasirox (type J)
Jadenu
Deferasirox Mylan
Sandoz Deferasirox
Sandoz Deferasirox (type J)
Jamp Deferasirox (type J)
Deferasorox
Teva-deferasirox
Auro-deferasirox (type J)
Deferasirox Accord
Exjade
Deferasirox
Taro-deferasirox
Teva-deferasirox (type J)
Deferasirox oral
Apo-deferasirox
PMS-deferasirox
Indication
For the treatment of chronic iron overload due to blood transfusions (transfusional hemosiderosis) in patients 2 years of age and older.
Categories
Acids, Carbocyclic
Benzene Derivatives
Benzoates
Chelating Agents
Compounds used in a research, industrial, or household setting
Drug Info/Drug Targets: DrugBank 3.0: a comprehensive resource for 'omics' research on drugs. Knox C, Law V, Jewison
T, Liu P, Ly S, Frolkis A, Pon A, Banco K, Mak C, Neveu V, Djoumbou Y, Eisner R, Guo AC, Wishart DS.
Nucleic Acids Res. 2011 Jan; 39 (Database issue):D1035-41. | PMID:21059682